Chronic hepatitis C
Conditions
Interventions
Administration of ribavirin without nucleoside transporter inhibitor
Administration of ribavirin with nucleoside transporter inhibitor
Sponsors
Tsukuba University Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Healthy male subjects 2) Older than 20 years, younger than 50 years 3) Weight less than 90 kg, and body mass index(BMI) of 18.5-25.0 4) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Anemia 2) Virus infection last 4 weeks prior to the study 3) Medication last 2 weeks prior to the study 4) Participation in a clinical trial last 3 months prior to the study 5) Intake of alcohol last 48 hours prior to the study 6) Blood donation more than 400 mL last 6 months prior to the study 7) Possible the autoimmune disease 8) Allergic reaction 9) Alcohol or drug abuse 10) Positive for HBs antigen, HCV antibody, and syphilis 11) Other inappropriate cases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetics of ribavirin | — |
Countries
Japan
Contacts
Public ContactYoshiharu Suzuki
Tsukuba University Hospital Pharmacy Department
Outcome results
None listed